Limits...
Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis.

Zhang YY, Tang Z, Chen DM, Gong DH, Ji DX, Liu ZH - BMC Nephrol (2014)

Bottom Line: Renal function and outcome were determined.Efficacy of clearing anti-GBM antibody was similar in the two groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%, p = 0.002).DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies.

View Article: PubMed Central - HTML - PubMed

Affiliation: National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, P, R, China. tang_dr@163.com.

ABSTRACT

Background: Double filtration plasmapheresis (DFPP) and (IA) are both used to clear antibody. However, the clinical efficacy and safety of DFPP in patients with anti-glomerular basement membrane (anti-GBM) disease are unclear.

Methods: The 28 enrolled patients diagnosed serologically and pathologically with anti-GBM disease from 2003 to 2013 included 16 treated with DFPP and 12 with IA, with all patients administered immunosuppressive agents. DFPP consisted of an EC50W filter for plasma separation and an EC20W filter for plasma fractionation. A double volume of plasma was processed, and each patient received a 30-40 g human albumin supplement during each session. IA consisted of 10 cycles per session, with 8-10 sessions performed daily or every other day and each session regenerating 30-60 L of plasma. Serum anti-GBM antibodies and IgG were measured, and urinary and blood tests were performed, before and after each procedure. Renal function and outcome were determined.

Results: The 28 patients consisted of 13 males and 15 females, of median age 44.5 years (range, 22.5-57 years). Six patients had pulmonary hemorrhage and 18 had serum creatinine concentrations >500 umol/L. The average serum creatinine concentration at early onset of disease was 525 umol/L while the peak concentration was 813 umol/L. All patients showed progressive increases in serum creatinine and required CRRT during the course of disease. Pathological examination showed an average 73.9% of crescents (range, 54.6-95.4%).The clinical and pathological features of the DPPP and IA groups were similar. Efficacy of clearing anti-GBM antibody was similar in the two groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%, p = 0.002). One patient each had a pulmonary hemorrhage and a subcutaneous hemorrhage during treatment, but there were no other serious complications. At the end of follow-up, patient survival and renal survival were similar in the DFPP and IA groups.

Conclusion: DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies. The fewer plasma-associated side effects and reduced loss of IgG suggest that DFPP may be a better treatment choice for anti-GBM disease, especially in patients with insufficient plasma.

Show MeSH

Related in: MedlinePlus

The patient survive and the renal survive were compared between the DFPP group and the IA group: the patient survival was similar. The renal survival of IA group was a little better than the DFPP group, but the difference was no significant between the two groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4127070&req=5

Figure 2: The patient survive and the renal survive were compared between the DFPP group and the IA group: the patient survival was similar. The renal survival of IA group was a little better than the DFPP group, but the difference was no significant between the two groups.

Mentions: Of the 16 patients in the DFPP group, 3 (18.8%) died at presentation or during follow-up; four (25.0%) were lost to follow-up; and nine (59.4%) progressed to end-stage renal disease (ESRD), with a median renal survival of 9 weeks (95% CI, 5–15 weeks). Five patients in this group (31.3%) progressed to CRF, while one returned to normal, being negative for anti-GBM antibody and on urine tests, and an SCr range of 67–86 μmol/L. Outcomes were similar in the two groups (Figure 2).


Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis.

Zhang YY, Tang Z, Chen DM, Gong DH, Ji DX, Liu ZH - BMC Nephrol (2014)

The patient survive and the renal survive were compared between the DFPP group and the IA group: the patient survival was similar. The renal survival of IA group was a little better than the DFPP group, but the difference was no significant between the two groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4127070&req=5

Figure 2: The patient survive and the renal survive were compared between the DFPP group and the IA group: the patient survival was similar. The renal survival of IA group was a little better than the DFPP group, but the difference was no significant between the two groups.
Mentions: Of the 16 patients in the DFPP group, 3 (18.8%) died at presentation or during follow-up; four (25.0%) were lost to follow-up; and nine (59.4%) progressed to end-stage renal disease (ESRD), with a median renal survival of 9 weeks (95% CI, 5–15 weeks). Five patients in this group (31.3%) progressed to CRF, while one returned to normal, being negative for anti-GBM antibody and on urine tests, and an SCr range of 67–86 μmol/L. Outcomes were similar in the two groups (Figure 2).

Bottom Line: Renal function and outcome were determined.Efficacy of clearing anti-GBM antibody was similar in the two groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%, p = 0.002).DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies.

View Article: PubMed Central - HTML - PubMed

Affiliation: National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, P, R, China. tang_dr@163.com.

ABSTRACT

Background: Double filtration plasmapheresis (DFPP) and (IA) are both used to clear antibody. However, the clinical efficacy and safety of DFPP in patients with anti-glomerular basement membrane (anti-GBM) disease are unclear.

Methods: The 28 enrolled patients diagnosed serologically and pathologically with anti-GBM disease from 2003 to 2013 included 16 treated with DFPP and 12 with IA, with all patients administered immunosuppressive agents. DFPP consisted of an EC50W filter for plasma separation and an EC20W filter for plasma fractionation. A double volume of plasma was processed, and each patient received a 30-40 g human albumin supplement during each session. IA consisted of 10 cycles per session, with 8-10 sessions performed daily or every other day and each session regenerating 30-60 L of plasma. Serum anti-GBM antibodies and IgG were measured, and urinary and blood tests were performed, before and after each procedure. Renal function and outcome were determined.

Results: The 28 patients consisted of 13 males and 15 females, of median age 44.5 years (range, 22.5-57 years). Six patients had pulmonary hemorrhage and 18 had serum creatinine concentrations >500 umol/L. The average serum creatinine concentration at early onset of disease was 525 umol/L while the peak concentration was 813 umol/L. All patients showed progressive increases in serum creatinine and required CRRT during the course of disease. Pathological examination showed an average 73.9% of crescents (range, 54.6-95.4%).The clinical and pathological features of the DPPP and IA groups were similar. Efficacy of clearing anti-GBM antibody was similar in the two groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%, p = 0.002). One patient each had a pulmonary hemorrhage and a subcutaneous hemorrhage during treatment, but there were no other serious complications. At the end of follow-up, patient survival and renal survival were similar in the DFPP and IA groups.

Conclusion: DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies. The fewer plasma-associated side effects and reduced loss of IgG suggest that DFPP may be a better treatment choice for anti-GBM disease, especially in patients with insufficient plasma.

Show MeSH
Related in: MedlinePlus